Summary of QQ2 2025 results for Groove Botanicals Inc (GRVE): The quarter shows a net loss of $29,833 with no revenue disclosed. Operating income and EBITDA are both -$29,833, highlighting a cost-heavy structure without revenue to cover expenses. Liquidity and balance sheet metrics signal an acute solvency risk, with cash of $6,133 against total current liabilities of $947,289 and total liabilities of $947,289 versus total assets of $11,125, producing a negative equity position of -$936,164. Financing activities provided a $46,219 inflow which contributed to a modest net cash increase of $3,495 for the quarter, but the business remains heavily reliant on external funding to sustain operations. Management commentary is not available in the provided transcript dataset, limiting qualitative insight into strategic pivots. Investors should view the stock as high-risk until a credible revenue path or a material capital infusion is disclosed. A potential upside would require a clear plan to monetize assets, raise additional capital, or implement a revenue-generating strategy that materially improves cash flow and lowers the negative equity burden.